Key facts
- This page summarizes Simon X. Benito's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 May 2024, 16:50.
Simon X. Benito - 21 May 2024 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)
- Reporting relationship
- Director
- Issuer ticker
- INO
- Reported as of
- 21 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 May 2024, 16:50:11 UTC
- Prior SEC filing
- 16 May 2024
- Next SEC filing
- 21 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Simon X. Benito
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Simon X. Benito filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 22 May 2024.
Change
- Previous filing in this sequence was filed on 16 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INO
transaction
Derivative
Common Stock Options
Award
- Transaction value
- $0
- Shares
- +2,917
- Change %
- Price
- $0.000000
- Shares after
- 2,917
- Date
- 21 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,917
- Exercise price
- $10.99
- Footnotes
- F1, F2
INO
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +2,167
- Change %
- Price
- $0.000000
- Shares after
- 2,167
- Date
- 21 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,167
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
Footnote F2
Options to vest 100% on May 21, 2025.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025.